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A B S T R A C T
Purpose: To describe the attributes of patients with Rasmussen’s encephalitis (RE) seen in a tertiary
epilepsy referral center in southern India and to enquire factors helpful in predicting responsiveness to
immunotherapy.
Methods: We diagnosed RE based on the European consensus criteria. To assess the factors that could
potentially predict the natural course and therapeutic outcome, we subcategorized our patients
according to age at onset (</> 6 years), duration from onset to presentation (</> 2 years),
immunotherapy versus surgery, and early (2 years from the onset) versus late surgery.
Results: The median age at disease onset of 19 patients was 6.0 years (range 2.3–13 years). Epilepsia
partialis continua (EPC) and hemiparesis were noted in 14 (73.6%) and 16 (84.2%) patients, respectively.
One patient, who presented with dysarthria due to tongue EPC, did not have hemiparesis despite having
had the disease for over 15 years. TheMRI ﬁndings inmajority conformed to stage 3 of Bien classiﬁcation.
While 9/10 patients treated by surgery achieved seizure-freedom, only 1/11 patients who received
immunotherapy did so. One patient expired due to subsequent development of contralateral
hemispheric disease following successful hemispherectomy. None of the factors such as age at onset,
age at presentation, presence/absence of antecedents, seizure burden, MRI stage predicted respon-
siveness to immunotherapy.
Conclusion: This study from a developing country, in addition to substantiating the well known
characteristics of RE, noted the following unusual ﬁndings: isolated lingual EPC abolished by focal
cortical resection, bilateral RE, putaminal atrophy and absence of hemiparesis despite long standing
disease.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Rasmussen’s encephalitis (RE) is a devastating disease char-
acterized by progressive unihemispheric affection resulting in
medically refractory focal seizures and contralateral neurological
deﬁcits.1,2 RE affects predominantly healthy children and pro-
gresses variably through a prodromal phase (with low seizure
frequency andmild or no hemiparesis), acute phase (with epilepsia
partialis continua and deteriorating limb weakness) and a residual
burnt-out phase (stable state with ﬁxed hemiparesis and reduced
seizure frequency).3 Although RE is usually a strictly unihemi-
spheric disease, there have been very rare occurrences of bilateral* Corresponding author at: Department of Neurology, Sree Chitra Tirunal
Institute for Medical Sciences and Technology, Trivandrum - 695 011, Kerala,
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1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.05.010disease.4 The European consensus statement on the pathogenesis,
diagnosis and treatment has recently proposed a diagnostic
criterion that has facilitated the diagnosis of RE (Table 1).5 Typical
cases with characteristic clinical, electrographic and radiological
features pose no diagnostic challenges and histopathological or
immunological studies are not routinely required to conﬁrm the
diagnosis of RE.5 However, diagnostic difﬁculties may arise with
atypical presentations especially very early into the illness.
The etiopathogenesis of RE is uncertain, although immune
mediated mechanisms are implicated.2,5 The nonspeciﬁc nature of
antibodies to glutamate receptor GluR3 which was initially
proposed to be associated with RE6 and the recent identiﬁcation
of antibodies toa-7-acetylcholine receptor in patients with biopsy
proven RE7 suggests that the syndrome of RE may encompass
several different autoimmune entities.8 With the description of
more and more patients with RE, the high variability in the clinical
course and neurological manifestations are becoming increasingly
apparent.3,5vier Ltd. All rights reserved.
Table 1
European consensus diagnostic criteria for Rasmussen’s encephalitis (RE).
Part A
(1) Clinical Focal seizures with or without EPC and unilateral cortical
deﬁcits
(2) EEG Unihemispheric slowing with or without IEDs and ictal
onset
(3) MRI Unihemisheric focal cortical atrophy plus at least one of
following:
Grey or white matter T2/FLAIR hyperintense signal
Hyperintense signal or atrophy of ipsilateral caudate
head
Part B
(1) Clinical EPC or progressive unilateral focal cortical deﬁcits
(2) MRI Progressive unihemispheric focal cortical atrophy
(3) Histopathology T cell dominated encephalitis with activated microglial
cells and reactive astrogliosis.
Numerous parenchymal macrophages, B cells or plasma
cells or viral inclusion bodies exclude the diagnosis of RE
Note: RE can be diagnosed if either all three criteria of Part A or two out of three
criteria of Part B are present. Adapted from Bien et al.5 EPC—epilepsia partialis
continua; IEDs—interictal epileptiform abnormalities.
K.N. Ramesha et al. / Seizure 18 (2009) 567–572568The seizures in RE are medically refractory and hemispher-
ectomy (variable anatomical resection of the involved hemisphere)
or hemispherotomy (unihemispheric disconnection) is often
required for seizure control.2,5 However, surgery is indicated only
in patients with contralateral motor deﬁcit and no useful hand
function. In patients unsuitable for surgery, immunotherapy with
corticosteroids, intravenous immunoglobulins or plasma exchange
is an initial alternative option.5,9,10 RE is very rare and major
epilepsy centers across the world do not encounter more than a
couple of cases annually.11 To the best of our knowledge, case
series with sizeable number of patients with RE has not been
reported from developing countries.
From a tertiary epilepsy center situated in southern India, we
report our experience with RE in 19 patients diagnosed over a span
of 11 years to address the following two questions: (1) are there
any demographical, clinical, electrophysiological, pathological and
imaging features that are peculiar to RE seen in this geographical
region? and (2) are there any factors that are helpful in predicting
the likelihood of patients’ responsiveness to immunotherapy vis-a`-
vis need for early surgical intervention?
2. Patients and methods
Utilizing a structured proforma, we abstracted the clinical,
investigative, therapeutic and follow-up data of patients diagnosed
with RE from January 1996 to March 2007 from the elaborate
prospective data base maintained at the R. Madhavan Nayar Center
for Comprehensive Epilepsy Care, Sree Chitra Tirunal Institute for
Medical sciences and Technology, Trivandrum, Kerala, southern
India. Diagnosis of RE was based on the diagnostic criteria
recommended by the European Consensus Statement (Table 1).5
Patients’ demographic proﬁle, birth history, perinatal insults,
antecedent illnesses, age at onset of seizures, age at presentation,
types of seizures, presence of epilepsia partialis continua (EPC,
deﬁnedas regular or irregular clonic twitchesaffectinga limitedpart
of the body lasting 1 h and recurring at intervals of <10 s),12
history of generalized convulsive status epilepticus, clinical ﬁndings
on examination during initial presentation and subsequent follow-
ups, age at onset of hemiparesis, electroencephalographic and
radiological features, progression of the disease, treatment given
and outcome were abstracted. In addition to routine scalp
electroencephalogram (EEG), prolonged video-EEG monitoring
was carried out in 17 patients. EEG data were reviewed by two
experiencedepileptologists associatedwith the study (RAandKR). A
neuroradiologist experienced in epilepsy neuroimaging and asso-ciated with the present study (CK) reviewed the MRI data of all
patients performed on a 1.5T scanner (Signa GE, Milwaukee, USA).
We staged the MRI abnormalities as proposed by Bien et al.13 as
follows: stage 0—no abnormality, stage 1—hyperintense signal and
swelling, stage 2—hyperintense signal and normal brain volume,
stage 3—hyperintense signal and atrophy, stage 4—normal signal
and progression of atrophy. Treatment decisions were taken after
discussing each case at the institutional epilepsy patient manage-
ment conference. Immunotherapy was considered in patients
having no or minimal neurological deﬁcits with reasonably
preserved distal upper extremity functions, in patients very early
into the illness with nondisabling seizures and those who declined
surgical therapy. Immunotherapy consisted of intravenous immu-
noglobulin (IVIG) at a dosage of at least 2 g/kg over 5 days or
intravenousmethyl prednisolone at a dosage of 20–30mg/day for at
least 5 days followed by oral steroids for a variable period of 12–24
weeks dependingon the response, or both IVIGandsteroids. Surgery
was offered in patients with medically refractory seizures and
contralateral hemiparesis with poor hand function. Either a
hemispherotomy which was the procedure of choice in patients
with cerebral atrophy or a hemispherectomy when there was no
atrophy of brain in which disconnection alone becomes technically
demanding was performed. In our center, the technique of
functional hemispherectomy includes a radical temporal lobectomy
and centro-parietal excision followed by total callosotomy and then
frontal and occipital disconnection. One of our patients with EPC of
tongue alone without any other deﬁcits, who underwent a limited
resection of the fronto-opercular cortex, has already been pub-
lished.14 Histopathological examination of the tissues obtained
during surgerywas undertaken by an experiencedneuropathologist
associated with the study (VVR). Patients under medical follow-up
were regularly followed up every 3 months after treatment, and
those who underwent surgery were followed up at 3months and at
12months and yearly thereafter. We classiﬁed the seizure outcome
following immunotherapy and surgery as seizure-free, and in those
with continuing seizures as percentage reduction in seizure
frequency compared to pre-treatment period and no change. The
patients were also assessed for their motor deﬁcit, cognitive
capabilities, schooling and employment.
2.1. Statistical analysis
We summarized the quantitative data as percentages, median,
range and mean  standard deviation (SD). Fisher’s exact test was
used for categorical variables andMann–Whitney test for continuous
variables for subgroup comparisons. A p value 0.05 was considered
as signiﬁcant.
3. Results
3.1. Demographic and clinical features
The demographic and clinical characteristics of our 19 patients
(12 males, 7 females) with RE are summarized in Table 2 and are
individualized in Table 3. The median age at disease onset was 6.0
years (range 2.3–13 years), while the median age at presentation to
us was 9 years (range 2.7–22 years). All patients were normal
neurologically prior to the onset of seizures. Antecedent eventswere
reported in seven children 1–2 weeks prior to the onset of the
seizures (febrile illness in four, vomiting and abdominal pain in two
and fall with insigniﬁcant head trauma in one). None had family
history of seizures. Seizures were the manifesting symptom in all
patients. Simple partial seizures (SPS) occurred in all, 16 (84.2%), in
addition had complex partial seizures (CPS). Eight patients (42.1%)
had history of recurrent generalized status epilepticus necessitating
frequent hospitalizations. EPC was noted in 14 (73.6%) patients. In
Table 2
Characteristics of 19 patients with Rasmussen’s encephalitis.
Gender (male:female) 12:7
Age at onset (year) Mean 6.0 + 2.8
(range 2.3–13.0)
Age at presentation (year) Mean 10.2 + 5.5
(range 2.7–22)
Hemisphere involved (right:left) 10:9
n (%)
Seizure types
Epilepsia partilis continua 14 (73.6)
Simple partial seizures 19 (100)
Complex partial seizures 16 (84.2)
Generalized tonic/clonic seizures 9 (47.3)
Recurrent convulsive status epilepticus 8 (42.1)
Neurological deﬁcit at presentation
Hemiparesis 16 (84.2)
Dysphasia 12 (63.2)
Hemianopia (n = 6) 6 (100)
Dysarthria 2 (10.5)
Interictal epileptiform EEG discharges
Ipsilateral 16 (84.2)
Contralateral 3 (15.7)
Ictal EEG onset (n = 17)
Lateralizing 15 (88.2)
Contralateral 2 (11.7)
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contralateral to hemispheric involvement. Hemiparesis of different
grades was observed in 16 (84.2%) patients. Hemiparesis occurred
after amean duration of 17.8months (range 7–22months) from the
onset of seizures. Three patients had no neurological deﬁcits
(Patients 8, 11, and 13, Table 3). None had ataxia, dystonia, chorea,
rigidity or other extrapyramidal symptoms or signs. Homonymous
hemianopia was noted in six patients in whom visual ﬁelds could
reliably be tested. Out of the 10 patients in whom sensory testing
could reliably be performed, two had hemihypestesia on the
hemiparetic side. A detailed neuropsychological assessment was
possible in only 12 children; they showed variable degree of
cognitive impairment. Out of the four patients aged >12 years, one
had a subnormal IQ of 50 (Patient 2, Table 3). Expressive and
receptive language dysfunction was noted in 12 (63.2%) patients,
three with right hemispheric involvement and nine with left
hemispheric involvement. In the three patients with right hemi-
spheric disease (Patients 2, 4 and 6, Table 3), the language
involvement was considered to be a part of the global cognitive
dysfunction theyhad. All our patientswere right handedprior to the
onset of the disease. Twopatients had dysarthria, one of themdue to
tongue EPCs (Patient 11, Table 3).
3.2. Electrophysiological data
Interictal epileptiform discharges (IEDs) were noted on the side
of hemispheric involvement in 16 patients (84.2%), but were seen
only over the contralateral hemisphere in three (15.7%). Inter-
ictally, unihemispheric background slowing was seen in 15
patients. Prolonged video-EEG monitoring done in 17 (89.4%)
patients recorded seizures arising from the affected hemisphere
(lateralizing) in 15 and false lateralized to the unaffected hemi-
sphere in two (Table 2).
3.3. Neuroimaging ﬁndings
The MRI ﬁndings of our patients are summarized in Table 4. The
interval from seizure onset to initial MRI ranged 1–80 months
(median 15 months). All had more than one MRI done at varyingintervals. Part of our radiological data has already been published.15
The insular and perisylvian cortex were maximally atrophic in all
(Fig. 1). Basal gangliawere affected in all, except onepatient (94.7%).
Caudate was atrophic in 17 patients (89.4%) while additional
putaminal atrophy was seen in 15 (78.9%) patients (Fig. 1). One
patienthad atrophy involving the globuspallidus aswell. Prominent
hyperintense signal changes on T2WI or ﬂuid attenuated inversion
recovery (FLAIR) sequences were noted in seven patients (36.8%)
(Fig. 1).Atrophyofcerebral peduncleandbrainstemipsilateral to the
affected hemisphere was noted in 11 patients (57.8%). None of our
patients had occipital involvement radiologically. A majority of our
patients belonged to stage 3 (15 patients, 78.9%) or stage 4 (three
patients, 15.7%) of Bien classiﬁcation.13 Gadolinium enhancement
was observed in none. Serial imaging revealed progressive hemi-
spheric atrophy 16 (84.2%) patients.
3.4. Treatment and outcome
Despite use ofmultiple AEDs (mean number of AEDs per patient
4.6, range 2–7), seizure control was poor in all. Immunotherapy
was attempted in 11 patients and surgery was undertaken in 10
patients. The outcomes ofmedically and surgically treated patients
are provided in Table 3.
3.4.1. Immunotherapy
Seven of 11 patients received intravenous methyl prednisolone
followed by oral steroids; two of them received IVIG prior to
steroid treatment. Two patients received IVIG alone. Two patients
had no beneﬁt (Patients 12 and 19, Table 3). Nine patients had
variable beneﬁts—one patient was seizure-free for 2 years with
subsequent relapse (Patient 7, Table 3). This patient had
improvement in hemiparesis as well. Four patients were operated
subsequently due to refractory disabling seizures. Two patients
had daily seizures but were not operated as there was no
hemiparesis (Patients 8 and 13, Table 3).
3.4.2. Surgery
Ten patients underwent either hemispherotomy (n = 6), hemi-
spherectomy (n = 3) or focal resection (n = 1). Histopathological
examination of the brain tissue showed variable degree of
perivascular lymphomononuclear aggregation, microglial nodules
and glosis (Fig. 1). During the mean follow-up duration of 2.7
(range 1–10) years, all of them had Engel class I outcome16 at last
follow-up, except onewho had seizure recurrence originating from
the left hemisphere 2 years after right hemispherectomy with
evidence of bilateral disease and succumbed to it (Patient 9,
Table 3). Seven of themwere seizure-free and aura-free during the
whole post-surgery follow-up period (Table 3). Out of nine patients
with left hemispheric disease and preoperative language dysfunc-
tion, three underwent surgery (Patients 3, 5 and 10, Table 3). Their
expressive and receptive language abilities showed a steady
improvement during the follow-up period. One patient with
tongue EPC and marked dysarthria regained normal articulation
after limited resection of frontal opercular region (Patient 11,
Table 3).14 Despite the absence of hemiparesis, severely disabling
dysarthria due to lingual EPC prompted this patient to consent for
this focal resection after fully understanding its uncertain long-
term beneﬁt. This patient continues to be free of lingual EPC and
dysarthria when seen recently 3 years after surgery. All except one
patient (Patient 2, Table 3), was ambulant at last follow-up, either
independently or with minimum support.
3.5. Predictors of outcome
Wegrouped patients into four categories for comparison, which
could potentially predict the natural course of RE and outcome:
Table 3







Neurological deﬁcit Treatment Duration of
follow-up (months)
Outcome at last follow-up
Immunotherapy Surgery
1 M/9 5 Right Hemiparesis, normal language MP – 120 50% reduction in seizures for 3 months
2 F/16 7.5 Right Hemiparesis, global cognitive and language
impairment
– Hemispherectomy 72 Rare nondisabling seizures, mild improvement in
cognition and language, in wheel chair, on one AED
3 F/8 6.5 Left Mild hemiparesis, dysphasia IG Hemispherectomy 48 Seizure-free, nearly normal language function, in
regular school, off AED
4 M/16 7 Right Hemiparesis, global cognitive and language
impairment
– Hemispherotomy 36 Seizure-free, improved language, in special school,
on one AED
5 M/11 2.5 Left Hemiparesis, dysphasia – Hemispherotomy 36 Seizure-free improved language, in regular school
6 F/4 3.4 Right Hemiparesis, global cognitive and language
impairment
IG + MP Hemispherotomy 36 Rare nondisabling seizures, improved language, in
special school, on one AED
7 F/6 3.5 Left Hemiparesis, dysarthria MP – 36 Seizure-free for 2 years, hemiparesis improved,
relapse with disabling seizures
8 M/4 3.5 Left No motor deﬁcit, dysphasia MP – 36 <25% reduction in seizures
9 M/8 6 Right! left Hemiparesis, global impairment – Hemispherectomy 24 Bilateral disease, expired
10 F/14 10 Left Hemiparesis, dysphasia – Hemispherotomy 24 Seizure-free, improved language, in special school,
on one AED
11 M/22 9 Right No hempiplegia, tongue EPC, dysarthria – Frontal opercular
resection
24 Tongue EPC abated, normal speech, employed
12 M/6 3.5 Left Mild hemiparesis dysphasia IG – 24 No change
13 M/15 8 Right No motor deﬁcit, normal language MP – 24 <25% reduction in seizures
14 M/4 3 Right Mild hemiparesis, normal language MP – 18 <50% reduction in seizures
15 M/13 7 Left Mild hemiparesis, dysphasia – – 18 >75% reduction in seizures
16 M/8 6 Right Mild hemiparesis, normal language MP Hemispherotomy 12 Seizure-free, in regular school
17 M/9 7 Right Mild hemiparesis Normal language MP Hemispherotomy 12 Seizure-free, in regular school, on one AED
18 F/18 13 Left Mild hemiparesis, dysphasia – – – No follow-up
19 F/2.7 2.3 Left Hemiparesis, dysphasia IG + MP – 3 No change































MRI abnormalities in 19 patients with Rasmussen’s encephalitis.
MRI ﬁndings n (%)
Insular and perisylvian atrophy 19 (100)
White matter hyperintense signal changes 7 (36.8)
Basal ganglia involvement 18 (94.7)
Caudate atrophy 17 (89.5)
Caudate + putaminal atrophy 15 (78.9)
Caudate + putaminal + globus pallidal atrophy 1 (5.3)
Atrophy of cerebral peduncle and brainstem 11(57.8)
MRI staging at presentationa
Stage 2 1 (5.2)
Stage 3 15 (78.9)
Stage 4 3 (15.7)
a MRI staging—see text and Bien et al.13 for deﬁnition.
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years (n = 11), duration from onset to presentation less than 2
years (n = 8) versus >2 years (n = 11), medical therapy versus
surgical therapy, and those who underwent surgery within 2
years from the onset (n = 3) versus >2 years. Among our patients,
antecedent events occurred more frequently in younger children
compared to those 6 years, although the difference did not quite
reach statistical signiﬁcance (5/8 vs. 2/11, p 0.07). While none of
the patients in themedical group achieved Engel class I outcome at
last follow-up, 9/10 in surgical group did so (p 0.000). At last
follow-up, none of the patients in medical group were on AEDFig. 1. The MRI and histopathological ﬁndings of a right handed 8-year-old girl (Patien
involving right upper and lower extremities. The right hemiparesis wasmild and she had
left hemisphere. Axial FLAIR (A) and T2W MR images (B) performed 6 months after ons
atrophy predominantly involving the insulo-opercular region, underlyingwhitematter h
horn. Because of repeated convulsive status epilepticus requiring hospitalizations unresp
hemispherectomy despite relatively preserved right upper limb motor functions and l
lympho-mononuclear cell inﬁltration (HE 200), (E) reactive gemsitocytic proliferation (
the postoperative aphasia within 3 weeks. When seen recently 5 years after surgery, she
left handedness because of suboptimal right hand ﬁne motor functions.monotherapy, whereas 5/9 patients in surgical group were
receiving only a single AED and one was totally off AED
(Table 3) (p 0.000). None of the variables such as age at onset,
presence of antecedents, pre-treatment seizure burden, MRI stage,
and extent of pre-treatment neurological deﬁcits predicted
responsiveness to immunotherapy.
4. Discussion
RE is a rare disease the world over. Our experience with 19
patients seen during 11-year period in a major epilepsy referral
center in southern India (1.7 cases per year) agreeswith those from
similar centers in developed countries.11 All our patients fulﬁlled
the European Consensus Diagnostic Criteria for RE.5 The diagnosis
was histopathologically veriﬁed in 10 of the operated patients. A
majority of our patients presented after median delay period from
disease onset of nearly 4 years, despite disabling medically
refractory seizures. SPS are the commonest seizure type in
RE.1,2,5 In addition, we noted a high frequency of CPS in 84% of
our patients, which contrasts with the observation of Oguni et al.,1
who reported CPS in only 50% of their patients. A higher frequency
of CPS in the present series of patients could be due to better
seizure characterization by video-EEGmonitoring. The presence of
chronic EPC is a useful diagnostic feature as it virtually narrows
down the differential diagnosis between RE and focal cortical
dysplasia, which can be easily distinguished by MRI. However,
absence of EPC does not exclude the diagnosis of RE; nearly one-t 3, Table 3) who presented with 18-month history of epilepsia partialis continua
nearly normal hand function. TheWada test conﬁrmed language lateralization to the
et of illness and coronal T2W sequence (C) 12 months later shows left hemispheric
yperintensity, caudate and putaminal atrophy, and enlargement of ipsilateral frontal
onsive to several antiepileptic drugs (AEDs) and immunotherapy, she underwent left
eft hemispheric speech dominance. Histopathology shows (D) dense perivascular
HE 150) and (F) microglial nodule (HE 200). She made a complete recovery from
is seizure- and AED-free, a ﬁfth grader doing well in school and has adapted well to
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has varied from 56% to 92% in different reports.1,5,17 One of our
patients in the burned out stage of RE had EPC restricted to left side
of the tongue, which was abolished by right frontal opercular focal
cortical resection.14 This patient, despite having had the disease for
over 15 years, did not exhibit any hemiparesis, as was true for one
more of our patients. Severely disabling dysarthria due to lingual
EPC prompted this patient to seek a limited focal resective
procedure after fully understanding its uncertain long-term
beneﬁt. During the last 3-year follow-up, this patient has remained
free of lingual EPC and dysarthria. Preservation of motor function
in some patients despite long standing disease could possibly be
explainable by neuronal plasticity, due to the transfer of motor
functions to uninvolved areas of diseased hemisphere or to
contralateral normal hemisphere. A similar mechanism may be
responsible for the steady improvement in expressive and
receptive language abilities we observed following surgery in
three of our patients with left hemispheric disease and pre-
operative dysphasia.
Bien et al.3 distinguished two groups of RE patients with
marked differences with regard to age at onset, duration of disease
and outcome. While their type 1 patients, with age at onset 6
years, had a rapid progression with disabling seizures and
neurological deﬁcits, type 2 patients with onset >6 years had
more slow and indolent course. There was a tendency for
antecedent events to occur more frequently in our patients with
age at onset 6 years. One of our patients who did not have
hemiparesis despite having had EPC for 16 years had age at onset of
focal seizures at 9 years. Although RE is essentially a unihemi-
spheric disease, bilateral RE very rarely occurs. Among 200
patients from the literature analyzed by Bien et al.5 evidence for
bihemispheric involvement was suggested in nine patients. One of
our patients, who presented with right hemispheric histopatho-
logically veriﬁed RE, developed right focal motor seizures after
being seizure-free for nearly 2 years following right hemispher-
ectomy. A computed tomography scan revealed left hemispheric
atrophy and white matter hyperdensities. The family did not
consent for any further investigation. The patient succumbed to
refractory seizures 4 years after the onset of left hemispheric
involvement.
Serial MRI showing progressive atrophy of the involved
hemisphere, most marked in the insular and periinsular regions
and ipsilateral head of the caudate nucleus is a pathgnomonic
diagnostic feature of RE.13,15,17 We observed prominent putaminal
involvement, in addition to the caudate involvement in 79% of our
patients (Table 3), which we have highlighted in an earlier
publication.15 Bien et al.13 have staged MRI abnormalities by
tracing their progression from normal to hyperintense signals and
cortical swelling to progressive cortical atrophy and disappearance
of hyperintense signals. The MRI ﬁndings in a majority of our
patients at presentation corresponded to stage 3 of Bien
classiﬁcation.13 Curiously, despite high frequency of caudate and
putaminal involvement, extrapyramidal features in RE is rare.5
None of our patients exhibited any extrapyramidal symptoms or
signs. A British study identiﬁed two out of six patients with RE
presenting with hemidystonia,18 although differentiation of tonic/
dystonic EPC from extrapyramidal dystonia can often be difﬁcult.
Surgery (hemispherectomy or hemispherotomy) is the deﬁni-
tive treatment of RE.2,5,19 In patients presenting early in the course
of the disease and in those without disabling hemiplegia are often
subjected to immunotherapy with steroids, intravenous immu-
noglobulin or plasma exchange.5,9,10 While the response to
immunotherapy on seizure burden is often inadequate and short
lived, seizure-freedom rates following surgery from 63% to 85%
have been reported.5 All expect one of our patients achieved Engel
class 1 outcome following surgery, while only one of 11 patientswho received immunotherapy had sustained seizure-freedom for
>2 years. None of the factors we analyzed, such as age at onset, age
at presentation, presence/absence of antecedents, seizure burden,
MRI stage, predicted responsiveness to immunotherapy. One may
have to resort to surgical intervention even in those patients with
little disabling neurological deﬁcits, if seizures are life threatening,
as happened in one of our patients illustrated through Fig. 1.
Although focal cortical resection has very little role in a progressive
unihemispheric disease like RE, it may be an option in selected
patients who manifests with EPC involving a restricted region in
the burned out stage of the disease, as exempliﬁed by our already
reported patient with lingual EPC.14
In summary, data from this series of patients from a developing
country reiterates the well known clinical, electrophysiological,
and radiological features of RE as well as the outcome following
immunotherapy and surgery. In addition, we observed the
following unusual features: isolated lingual EPC abolished by
focal cortical resection, development of contralateral hemispheric
disease following successful hemispherectomy, absence of hemi-
paresis despite long standing disease, and MRI evidence for high
frequency of putaminal atrophy, in addition to the caudate head
atrophy.
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